{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:47:04Z","timestamp":1786963624305,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102185","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:34:23Z","timestamp":1723167263000},"page":"102185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS\u2014Meet-URO 26 Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2071-8971","authenticated-orcid":false,"given":"Giuseppe","family":"Fotia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Saieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-6046","authenticated-orcid":false,"given":"Richard","family":"Lee-Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8079","authenticated-orcid":false,"given":"Pier Vitale","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davidsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5695","authenticated-orcid":false,"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2396","authenticated-orcid":false,"given":"Talal","family":"El Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4363-6274","authenticated-orcid":false,"given":"Gian Paolo","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Damassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Murianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Vauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Martins","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malgeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikol","family":"Modesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Pereira","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loana","family":"Valenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":false,"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-7023","authenticated-orcid":false,"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102185_sbref0001","series-title":"Estimated Number of New Cases: Age-Specific Tables 2020. GLOBOCAN","year":"2020"},{"issue":"1","key":"10.1016\/j.clgc.2024.102185_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.clgc.2024.102185_sbref0003","series-title":"Prostate Cancer","year":"2021"},{"issue":"6","key":"10.1016\/j.clgc.2024.102185_bib0004","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ctrv.2012.12.004","article-title":"New treatment developments applied to elderly patients with advanced prostate cancer","volume":"39","author":"Mukherji","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clgc.2024.102185_bib0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ctrv.2009.04.014","article-title":"Treatment of prostate cancer in unfit senior adult patients","volume":"35","author":"Falci","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.clgc.2024.102185_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11864-011-0160-6","article-title":"Treating prostate cancer in elderly men: how does aging affect the outcome?","volume":"12","author":"Shelke","year":"2011","journal-title":"Curr Treat Options in Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2024.102185_bib0007","doi-asserted-by":"crossref","first-page":"e19760","DOI":"10.1097\/MD.0000000000019760","article-title":"Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis","volume":"99","author":"He","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.clgc.2024.102185_bib0008","series-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.4.2024","year":"2024"},{"key":"10.1016\/j.clgc.2024.102185_bib0009","unstructured":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2024. Available at: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk. Accessed July 26, 2024."},{"issue":"9","key":"10.1016\/j.clgc.2024.102185_bib0010","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clgc.2024.102185_bib0011","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.3390\/curroncol30090591","article-title":"A real-world evidence study using alberta-population-based data to describe treatment patterns for metastatic castration-sensitive prostate cancer patients (AWARENESS)","volume":"30","author":"Karim","year":"2023","journal-title":"Curr Oncol"},{"issue":"Supplement 5","key":"10.1016\/j.clgc.2024.102185_bib0012","first-page":"e1115","article-title":"MP68-16 Real world treatment patterns and outcomes of patients with metastatic castration-resistant prostate cancer stratified by prior novel hormonal therapy and taxane use","volume":"211","author":"Swami","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102185_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102185_bib0014","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102185_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102185_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12967-022-03861-2","article-title":"Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer","volume":"21","author":"Nuzzo","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.clgc.2024.102185_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156147","article-title":"Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer","volume":"15","author":"Nuzzo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102185_bib0018","first-page":"552","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"78","author":"Cornford","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102185_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2024.102185_bib0020","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.clgc.2024.102185_bib0021","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.21.00165","article-title":"Decision making in older adults with cancer","volume":"39","author":"DuMontier","year":"2021","journal-title":"JCO"},{"issue":"24","key":"10.1016\/j.clgc.2024.102185_bib0022","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.55.1531","article-title":"Prostate cancer in the elderly patient","volume":"32","author":"Fung","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2024.102185_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221149887","article-title":"Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review","volume":"15","author":"Mir","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2024.102185_bib0024","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102185_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clgc.2017.12.012","article-title":"Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy + docetaxel or ADT alone for metastatic hormone-sensitive prostate cancer","volume":"16","author":"Francini","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2024.102185_bib0026","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102185_bib0027","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.juro.2015.07.004","article-title":"Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"194","author":"Smith","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102185_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug\u2013drug interaction potential in men treated with enzalutamide: mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Brit J Clin Pharma"},{"issue":"2","key":"10.1016\/j.clgc.2024.102185_bib0029","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:58:31Z","timestamp":1738565911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001563"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102185","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS\u2014Meet-URO 26 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102185"}}